New hope for Hard-to-Treat lymphoma: targeted drug shows promise

NCT ID NCT05296070

Recruiting now Disease control Sponsor: University of Miami Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called loncastuximab tesirine in 50 adults with marginal zone lymphoma that has returned or not responded to prior treatments. The drug is given as an IV infusion over several cycles. Researchers want to see if it can shrink tumors and control the disease for at least 6 to 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: loncastuximab tesirine
What this could lead to: If it works, this could offer a new treatment option for people with marginal zone lymphoma that has not responded to other therapies.
What could go wrong: This is a small, early-phase trial with only 50 participants. The drug may not work for everyone, and side effects like swelling or fatigue are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MARGINAL ZONE LYMPHOMA

Contacts and locations

Locations

City of Hope National Medical Center
RECRUITING

Duarte, California, 91010, United States
Emory University
RECRUITING

Atlanta, Georgia, 30322, United States
University of Miami
RECRUITING

Miami, Florida, 33136, United States
Vanderbilt University
RECRUITING

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.